[Intravitreal injection. Monitoring to avoid postoperative complications].
Intravitreal injection is generally regarded as safe. Many of the potential complications caused by this procedure are extremely rare and can be avoided by careful inspection beforehand and proper performance of the injection. In rare cases, however, the administered drugs may cause various pharmacological side effects. This article summarizes the safety profiles of Macugen and Lucentis from the drug approval studies and describes initial findings on possible or observed side effects after intravitreal administration of Avastin. In addition, important points to observe in order to avoid intra- and postoperative complications are provided.
Meyer
C H
CH
Augenklinik, Universitätsklinikum Bonn, Ernst-Abbe-Strasse 2, 53127, Bonn, Germany. carsten_h.meyer@ukb.uni-bonn.de
Ziemssen
F
F
Heimann
H
H
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000008:administration & dosage* / Q000009:adverse effects*; D000068258:Bevacizumab; D002386:Cataract / Q000139:chemically induced; D017326:Clinical Trials, Phase III as Topic; D009877:Endophthalmitis / Q000139:chemically induced; D005130:Eye Hemorrhage / Q000139:chemically induced; D005260:Female; D005333:Fetus / Q000187:drug effects; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D008268:Macular Degeneration / Q000188:drug therapy; D051379:Mice; D019152:Paracentesis; D011183:Postoperative Complications / Q000517:prevention & control*; D011247:Pregnancy; D011817:Rabbits; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D012163:Retinal Detachment / Q000139:chemically induced; D014605:Uveitis / Q000139:chemically induced; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab